Moderna (MRNA) Equity Average (2017 - 2026)
Moderna (MRNA) has disclosed Equity Average for 10 consecutive years, with $8.0 billion as the latest value for Q1 2026.
- For Q1 2026, Equity Average fell 23.41% year-over-year to $8.0 billion; the TTM value through Mar 2026 reached $8.0 billion, down 23.41%, while the annual FY2025 figure was $9.8 billion, 21.02% down from the prior year.
- Equity Average hit $8.0 billion in Q1 2026 for Moderna, down from $9.0 billion in the prior quarter.
- Across five years, Equity Average topped out at $19.0 billion in Q1 2023 and bottomed at $8.0 billion in Q1 2026.
- Average Equity Average over 5 years is $13.6 billion, with a median of $13.3 billion recorded in 2024.
- Year-over-year, Equity Average soared 387.89% in 2022 and then tumbled 31.51% in 2024.
- Moderna's Equity Average stood at $18.6 billion in 2022, then dropped by 26.42% to $13.7 billion in 2023, then dropped by 16.41% to $11.4 billion in 2024, then dropped by 21.24% to $9.0 billion in 2025, then fell by 10.69% to $8.0 billion in 2026.
- According to Business Quant data, Equity Average over the past three periods came in at $8.0 billion, $9.0 billion, and $9.4 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.